News

Filter

Abide Therapeutics in up to $430 million deal with Merck & Co for type 2 diabetes and metabolic disease

03-05-2013

Privately-held biopharma firm Abide Therapeutics has entered into a collaboration agreement with US…

Abide TherapeuticsDiabetesLicensingMerck & CoMetabolicsPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top